OUR FACILITIES
WILL REMAIN OPEN & OPERATIONAL DURING THE COVID-19 PANDEMIC

Cell and gene therapies may be considered novel by the general public today, but they are on the path to dramatically improve the lives of those with chronic conditions and cancers. While a handful of therapies have bene commercialized, hundreds of these therapies are currently being administered to patients in clinical trials, and the FDA is likely to approve nearly two dozen more by 2023.  

Biopharmaceutical supply chains are among the most complex and costly processes on the planet. CAR T-cell therapies, which can cost hundreds of thousands of dollars to create, can be rendered ineffective with even the slightest temperature deviation during the lengthy apheresis, manufacturing and final product logistics process. The stakes couldn’t be higher: not only is a costly medical therapy on the line, but often, so is a patient’s life. 
 
Recognizing this high risk of failure, biopharmaceutical companies are increasingly customizing aspects of their supply chains. Whether they’re creating unique equipment, packaging, or data reports, they’ve turned to Cryoport’s experts to increase control, understanding and efficacy of the development and distribution process.